As demand for Investigator-Initiated Trials (IITs) and advanced therapies continues to grow, biopharma sponsors frequently encounter challenges related to operational efficiency, regulatory compliance...
Recently, Santen Pharmaceutical (global leadership from Japan, US, and China) visited GCP ClinPlus for in‑depth discussions on data management, FSP collaboration, and AI applications in clinical deve...
Dr Long Jiang is the CEO of GCP ClinPlus, a Chinese CRO with operations in New Jersey. A former cardiovascular surgeon at Peking University People's Hospital, he shifted into clinical research aft...
On July 3, China’s National Medical Products Administration (NMPA) officially approved Gensci Pharma’s Class 1 innovative drug—fusincimab (brand name: Jinbeixin®). As China’s first independently ...
On July 3, China’s National Medical Products Administration (NMPA) officially approved Gensci Pharma’s Class 1 innovative drug—fusincimab (brand name: Jinbeixin®). As China’s first independently ...
When dry eye patients suffer from recurring dryness and stinging, the launch of a new drug could be the key to transforming their quality of life. Recently, a major milestone emerged in China’s dry ...
